The BIO CEO & Investor Conference

BIO recently hosted the 15th annual BIO CEO & Investor Conference at the Waldorf Astoria New York, the largest investor conference focused on established and emerging publicly traded and select private biotech companies. This year’s event drew more than 1,200 industry leaders, welcomed over 750 investors and facilitated at least 1,300 One-on-One Partnering meetings. BIO’s successful portfolio of investor conferences includes the BIO Investor Forum taking place in San Francisco later this year.

Mark your calenders for next year: Feburary 10th - 11th, 2014.

Fireside Chat with Robert Hugin, Chairman and Chief Executive Officer, Celgene Corporation

Celgene CEO on New Multiple Myeloma Drug Approvals
FDA approval of Pomalyst is a big advancement for patients and the drug is very complementary to Celgene’s current myeloma program, Hugin explained.

Word on the Street: The Buy-Side View for 2013

Word on the Street – Biotech Stocks Only Have Room to Go Up
When evaluating a stock and its market value, the need for access to the best and most current information is crucial.

Fireside Chat with John Lechleiter, PhD, Chairman, President & CEO, Eli Lilly

How to Survive the Patent Cliff: Eli Lilly’s CEO at the BIO CEO & Investor Conference
Like a number of companies, Eli Lilly is confronting a wave of patent expirations called the patent cliff.

Small Companies Thinking Big: China Tactical Strategies

Small Biotech Companies and China: 5 Keys to Success
“Relationship building takes very, very long. Don’t talk about any transaction within the first 6 months,” Zhang said. “You have to dine and wine… and sometimes you have to do karaoke!”

Fireside Chat with N. Anthony Coles MD, Chairman & CEO, Onyx Pharmaceuticals

Onyx CEO One of 25 Most Influential People in Biopharm Today According to FierceBiotech
Coles contributes a majority of Onyx’s success to two things: a strong mix of collaborations which has allowed business to move rapidly and the continued effort to remain opportunistic.

Orphan Drugs: Making Rare Disease Rarer

The signing of FDASIA by President Obama in July reinforces the country's commitment to fostering innovation for rare diseases. With a record 460 medicines in late-stage clinical trials, biopharmaceutical companies have embraced rare disease medicine and are rapidly developing the pipeline with hopes of achieving the ever elusive blockbuster drug.

Fireside Chat with John Milligan, PhD, President and Chief Operating Officer, Gilead Sciences

Despite Low Funding, Biotech Productivity Remains High In 2013
“What I’m seeing at Gilead is very interesting…  it’s a real explosion in productivity. We’re seeing great molecules coming through in our HCV portfolio. I think I’ve seen some of the best things that will probably never be drugs come out, because I think the field is moving that fast that we won’t need them.”

Putting a Ring on It - When Drug Development Deals Turn into Acquisitions

Putting a Ring on It: Advice on Successful Drug Development Collaborations
Drug development partnerships can look lucrative to small biotechs eager to monetize their discoveries, but, like any relationship, these tie-ups take work and both parties run the risk of ending up in tears…

Fireside Chat with Jean-Jacques Bienaimé, CEO, BioMarin

Mr. Bienaimé joined BioMarin in May 2005 as chief executive officer and member of the board of directors, bringing with him over 25 years of experience in the biotechnology and pharmaceutical industries. Under his leadership, the market capitalization of BioMarin went from around $450 million in May 2005 to over $4.5 billion in the summer of 2012. BioMarin 2012 revenues are anticipated to be approximately $500 million. BioMarin is a fully integrated biopharmaceutical company with over 1000 employees.

Tales From the Wild West (Wing): Reflections from White House Chiefs of Staff

The election chips have fallen and the country is gearing up for another four years of economic challenges and political wrangling. With divided government, compromises will be difficult and time consuming to reach, but will be necessary to deal with big issues the U.S. faces.